Early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trial

Abstract

Introduction

Sub-Saharan Africa shoulders the highest burden of global sepsis and associated mortality. In high HIV and tuberculosis (TB) prevalent settings such as sub-Saharan Africa, TB is the leading cause of sepsis. However, anti-TB therapy is often delayed and may not achieve adequate blood concentrations in patients with sepsis. Accordingly, this multisite randomised clinical trial aims to determine whether immediate and/or increased dose anti-TB therapy improves 28-day mortality for participants with HIV and sepsis in Tanzania or Uganda.

Methods and analysis

This is a phase 3, multisite, open-label, randomised controlled clinical 2×2 factorial superiority trial of (1) immediate initiation of anti-TB therapy and (2) sepsis-specific dose anti-TB therapy in addition to standard of care antibacterials for adults with HIV and sepsis admitted to hospital in Tanzania or Uganda. The primary endpoint is 28-day mortality. A sample size of 436 participants will provide 80% power for testing each of the main effects of timing and dose on 28-day mortality with a two-sided significance level of 5%. The expected main effect for absolute risk reduction is 13% and the expected OR for risk reduction is 1.58.

Ethics and dissemination

This clinical trial will determine the optimal content, dosing and timing of antimicrobial therapy for sepsis in high HIV and TB prevalent settings. The study is funded by the National Institutes of Health in the US. Institutional review board approval was conferred by the University of Virginia, the Tanzania National Institute for Medical Research, and the Uganda National Council for Science and Technology. Study results will be published in peer-reviewed journals and in the popular press of Tanzania and Uganda. We will also present our findings to the Community Advisory Boards that we convened during study preparation.

Trial registration number

ClinicalTrials.gov (NCT04618198).

Correspondence to Dr Christopher C Moore; [email protected]

Strengths and limitations of this study

• The 2×2 factorial design of this pragmatic trial of immediate initiation of anti-tuberculosis (TB) therapy and sepsis-specific dose anti-TB therapy will inform on the optimal content, dosing and timing of antimicrobial therapy for adult sepsis in HIV and TB endemic settings.

• Distinct clinical trial phenotypes coupled with comprehensive molecular evaluation of alternative pathogens of sepsis (by our multiplex Febrile Illness TaqMan Array Card-TAC) will allow for prespecified subgroup analyses of those with confirmed TB.

• A pharmacokinetic (PK) analysis of the subset of participants receiving immediate anti-TB therapy will determine whether sepsis-specific dose anti-TB therapy will significantly increase serum concentrations of rifampin and isoniazid and if those with confirmed TB sepsis and PK parameters within target range have a significantly faster time to clinical improvement.

• This pragmatic trial is endorsed by community advisory board members.

• A limitation of this randomised controlled trial of antimicrobial therapy for adult sepsis in sub-Saharan Africa is lack of blinding.

Introduction

Sepsis is a syndrome of critical illness defined as life-threatening organ dysfunction due to a dysregulated host response to infection and is the leading cause of global mortality.¹ In 2017, the WHO made sepsis a global health priority.² The highest burden of sepsis occurs in low-income and middle-income countries, and specifically in sub-Saharan Africa where there are at least 1.2–2.2 million cases of sepsis and 6.5 million deaths due to infection annually.^{3 4} The majority of these patients are living with HIV. Although little is known about sepsis in the global South, we have determined that the leading cause of sepsis in this region is Mycobacterium tuberculosis (TB), which is responsible for 25%–30% of bloodstream infections in septic patients⁵ (figure 1). TB sepsis is associated with 20%–50% case fatality rates with the majority of deaths occurring within the first 4–5 days of hospital admission.⁶ However, it is difficult to identify TB sepsis clinically or with diagnostic tests, which are often unavailable and have limited sensitivity. Therefore, TB can be missed and patients with TB sepsis may not receive anti-TB therapy, or if they do, treatment initiation may be delayed.

Figure 1. Pyramid figure demonstrating the estimated prevalence of (A) community-acquired bloodstream infections in severely ill adults in industrialised countries versus (B) high TB-HIV burden settings in sub-Saharan Africa. Adapted from Int J Tuberc Lung Dis 2015 Oct;19(10):1128-34 with permission.

We found that empirical treatment of TB in septic patients in Uganda without a confirmed diagnosis of TB was associated with improved 28 day mortality.⁷ Importantly, however, pharmacokinetics (PK) and pharmacodynamics studies of anti-TB therapy in hospitalised patients have shown low circulating drug concentrations that are suboptimal for microbial kill.^{8 9} Therefore, our hypotheses are that immediate anti-TB therapy will improve 28-day mortality compared with anti-TB therapy that is administered only after a diagnosis is made, and that optimised sepsis-specific dosing will improve 28-day mortality compared with conventional WHO recommended weight-based dosing regardless of the timing of administration.

We will test these hypotheses through A randomised clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa (ATLAS trial). This ATLAS trial is strongly endorsed by Tanzanian and Ugandan community advisory boards and will be the first to determine the optimal content, dosing and timing of the antimicrobial regimen for adult sepsis in sub-Saharan Africa.

Methods and analysis

Study design

The ATLAS trial is a phase 3, multisite, open-label, randomised controlled clinical 2×2 factorial superiority trial of (1) immediate initiation of anti-TB therapy and (2) sepsis-specific dose anti-TB therapy in addition to standard of care antibacterials for adults with HIV and sepsis admitted to our study sites at Kibong’oto Infectious Diseases Hospital in Tanzania or Mbarara Regional Referral Hospital in Uganda (figure 2). The primary endpoint is 28-day mortality and the secondary endpoints include in-hospital mortality, 6-month mortality, time to death, duration of hospitalisation, time to anti-TB therapy, adverse drug events during the 28-day study period, final sepsis aetiology, time to ambulation and temperature normalisation, Karnofsky score, and rifampin and isoniazid peak concentrations (Cmax) and total exposures as determined by the area under the concentration–time curve (AUC 0–24 hours). A sample size of 436 participants will provide 80% power for testing each of the main effects of timing and dose on 28-day mortality with a two-sided significance level of 5%. The expected main effect for absolute risk reduction is 13% and the expected OR for risk reduction is 1.58.

Figure 2. Schema of the ATLAS trial. ART, antiretroviral therapy; ATLAS, A randomised clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa; MAP, mean arterial pressure; SBP, systolic blood pressure; TAC, TaqMan Array Card.

Study population

Study participants will be recruited consecutively from each study site hospital and enrolled if they provide consent, are ≥18 years old, living with HIV, and are found to have sepsis defined as (1) clinical concern for infection, (2) ≥2 modified quick sepsis related organ failure assessment (qSOFA) score criteria including respiratory rate ≥22; GCS score <15; or systolic blood pressure ≤90 or mean arterial pressure ≤65 mm Hg.^{10 11} We are using a modified qSOFA score to maximise both clinical simplicity as part of this pragmatic trial and to select participants who are at the highest risk of death and therefore the most likely to benefit from early empirical anti-TB therapy.^{7 10 12 13} Study participants found to have a positive serum cryptococcal antigen test will be excluded as they would have a high expected case fatality rate and among those receiving anti-TB therapy would bias the study outcome to a null result whether or not they also had TB.¹⁴ We will also exclude potential participants with known active TB or who have received TB treatment in the 6 months preceding the time of presentation to the hospital (including isoniazid preventive therapy), pregnant or lactating women, and those with known liver disease or significant alcohol use.

Interventions

After participants have been screened and consented to join the study, they will be randomised by a computer-generated, permuted-block randomisation algorithm with random block sizes of 4 and 8 in a 1:1:1:1 ratio stratified according to site and the presence or absence of altered mental status at the time that informed consent was obtained. Randomisation and data capture and storage will be conducted via research electronic data capture (REDCap) software. The two treatment randomizations include (1) immediate initiation of anti-TB therapy plus standard care or diagnosis-dependent anti-TB therapy plus standard care, and (2) sepsis-specific dosed anti-TB therapy with rifampin (~30 mg/kg), isoniazid (~7.5 mg/kg), pyrazinamide, and ethambutol using a combination of single dose (isoniazid and rifampin) and fixed dose combination tablets, plus pyridoxine or conventional WHO recommended weight-based anti-TB therapy with rifampin (~10 mg/kg), isoniazid (~5 mg/kg), pyrazinamide, and ethambutol in fixed dose combination tablets, plus pyridoxine, as recommended by WHO’s ‘Treatment of Tuberculosis Guidelines’ and the Uganda and Tanzania Ministries of Health.¹⁵ All participants receive serial blood testing to monitor for adverse events possibly associated with study interventions (table 1).

Table 1

Schedule of events for the ATLAS trial

Data collection instrument	Screening/enrolment Day 1	Day 2	Day 3	Day 7	Day 14	Day 21	Day 28	Discharge	6 Months	Unscheduled visit
Screening	·
Verification of consent	·
Randomisation	·
Baseline chart review	·
Vital signs	·	·	·	·	·	·	·	·	·	·
Baseline medical assessment	·
Concomitant medication review	·	·	·	·	·	·	·	·	·	·
Baseline specimen collection	·	·
Study drug medications follow-up		·	·	·	·	·	·	·	·	·
Follow-up outcomes		·	·	·	·	·	·	·		·
Follow-up specimen collection				·	·	·	·			·
6 month follow-up									·
PK sampling			·

ATLAS, A randomised clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa; PK, pharmacokinetic.

Participants not randomised to immediate initiation of anti-TB therapy but who are subsequently found to have TB by WHO-recommended TB tests (sputum and urine Xpert MTB/RIF Ultra, Alere Determine LF-Lipoarabinomannan (LAM) and/or TB culture) or clinically diagnosed with TB will receive anti-TB therapy with the dosing to follow the ‘Randomization 2’ assignment (figure 2). Hence, the 2×2 factorial design will create four distinct study groups: (1) immediate empirically initiated conventional anti-TB dose treatment, (2) immediate empirically initiated sepsis-specific anti-TB dose treatment, (3) diagnosis-dependent conventional anti-TB dose (only administered if ultimately confirmed or clinically suspected to have TB), and (4) diagnosis-dependent sepsis-specific anti-TB dose (only administered if ultimately confirmed or clinically suspected to have TB). According to the WHO Integrated Management of Adolescent/Adult Illness Guidelines for severe infections, ceftriaxone is the first-line recommended agent for the treatment of bacterial sepsis, as it treats the most common non-TB bacterial pathogens.¹⁶ Thus, all study participants will be administered ceftriaxone for 7 days, but clinicians may alter this portion of the treatment regimen as needed based on the clinical scenario.

Participants receiving anti-TB therapy (conventional or sepsis-specific dose) will receive anti-TB therapy per protocol until 28 days to coincide with the evaluation of the primary endpoint of 28-day mortality, which is a frequently used endpoint for sepsis trials and allows for close follow-up in our study settings.¹⁷ Study personnel will be responsible for linkage of all participants and their TB test results to the local antiretroviral/TB clinic where their care will be managed from 28 days forward. We anticipate that the overwhelming majority of study participants who receive TB treatment and survive to the 28-day evaluation will be continued on conventional TB treatment but stakeholders in Tanzania and Uganda preferred this decision to be made independent of the study team. Study participants randomised to sepsis-specific anti-TB therapy dosing who continue on anti-TB therapy after 28 days will revert to conventional WHO recommended weight-based dosing. Participants not randomised to empiric immediate initiation anti-TB therapy who do not subsequently receive anti-TB therapy will be linked to care for consideration of isoniazid preventive therapy at 28 days.

Diagnostic testing, procedures and definitions

The trial was open for enrollment on 4 June 2021. The duration of the trial is expected to last 36 months. Study procedures start at screening and continue through 6 months of follow-up (table 1). Data will be entered into a REDCap software database. Study personnel at each site will complete informed consent forms, case report forms, and data collection tools according to standard operating procedures and as determined by regulatory authorities. All study documents will be stored securely at the study sites for a minimum of 5 years. If a protocol change is required, it will be submitted to the relevant ethics committees for approval.

At enrolment, all participants will undergo sampling of blood, sputum, and urine to identify the aetiology of sepsis through conventional microbiological methods and novel assays and for future biomarker studies. Conventional methods will include culture of blood (BacTec 9050), sputum, and urine for bacteria. For evaluation of TB, all participants will have WHO-approved rapid TB diagnostics including GeneXpert MTB/RIF Ultra on sputum and urine, Alere Determine LF-LAM on urine, as well as mycobacterial culture of sputum (MGIT 960 system) and blood (BACTEC Myco/F system). Serum cryptococcal antigen will be tested on blood from all potential participants prior to enrollment. Rapid malaria testing and other targeted pathogen testing will be at the discretion of the treating clinician. Novel diagnostics will include the use of the multiplex TaqMan Array Card (TAC) assay which targets 44 pathogens associated with febrile illness in East Africa, to be run in batch analysis⁵ (figure 3). The final aetiology of sepsis will be defined as ‘confirmed TB sepsis’ if any of the rapid diagnostic tests (Xpert MTB/RIF Ultra, Alere Determine LF-LAM, sputum AFB smear) are positive, or if M. tuberculosis complex is identified by mycobacterial culture or TAC assay; ‘non-TB sepsis’ if the bacterial cultures or TAC assay identify a causative pathogen (excluding cytomegalovirus or Plasmodium species monoinfection by TAC card, as these may be co-occurring infections that are not primary drivers of sepsis in adults); and ‘unconfirmed sepsis’ if all diagnostic assays are negative.^{5 18}

Figure 3. Example of a quantitative PCR-based TaqMan Array Card used to determine aetiology of bloodstream infection in the ATLAS trial. ATLAS, A randomised clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa.

Data analysis plan

The survival time for each participant will be defined as the time from randomisation until death, discharge (alive) prior to 28 days, or censored (alive) at day 28. Kaplan-Meier curves will be used to estimate the survival distribution. Comparisons at day 28 will be based on survival estimates and standard errors after complementary log–log transformation. Subsequent confirmatory analyses will use Cox proportional hazards models to estimate the main effects of timing and dose, adjusting for the stratification factors (site and altered mental status) and whether or not the participant tested positive for TB. A second proportional hazards model will also be fitted, which will estimate main effects of timing and dose and add participant characteristics at baseline to the previous model. While the analyses are focused primarily on the main effects, subsequent exploratory analyses will estimate and test for interactions between timing and dose.

For in-hospital mortality, we anticipate no censoring and Χ² tests will be used to compare the randomised treatment groups. Subsequent analyses will use logistic regression to compare in-hospital mortality among the randomised treatment groups, adjusting for participant characteristics. For 6-month mortality, we anticipate that many observations will be censored prior to 6 months, that is, participants are known to be alive at a point prior to 6 months but are lost to follow-up prior to the 6 month visit. The analyses for this endpoint will be the same as for the primary 28-day mortality, in which we will estimate and compare the survival curves among the groups at a specific point in time (6 months). For other ‘time-to-event’ endpoints, including duration of hospitalisation, time to ambulation, time to temperature normalisation, and time to anti-TB therapy (within the diagnosis-dependent groups), the substantial level of mortality requires that mortality be taken into account in comparing the time-to-events distributions among groups.¹⁹

For comparing adverse events, the proportion of participants experiencing at least one adverse drug event will be tabulated and compared with a Χ² test. Subsequent analyses will use logistic regression to compare the proportions adjusting for clinical and laboratory variables. Χ² tests will also be used to compare the groups with respect to the final sepsis aetiology. Methods for ordinal categorical variables, such as the proportional models, will be used to compare the groups with respect to Karnofsky score. The assumptions underlying this model will be checked and if the proportional odds assumption does not hold, continuation ratio models will be used. Subsequent analyses will add clinical and laboratory variables to compare the groups after adjusting for these variables.

For the analysis of the subset of participants undergoing PK testing, we hypothesise that sepsis-specific dose anti-TB therapy will significantly increase serum concentrations of isoniazid in the early treatment interval compared with conventional dosing, and >95% of participants treated with sepsis specific dosing for rifampin will have Cmax and AUC at or above target values. Furthermore, those with confirmed TB sepsis and PK parameters within target range are expected to have a significantly faster time to clinical improvement. We will select those participants randomised to immediate anti-TB initiation to have timed blood sampling on day-2 after treatment and perform PK testing on all (n=218). We will collect four venous blood draws within the dosing interval (1, 2, 4 and 6 hours after medication administration). Serum will be stored at −80°C and serum concentrations will be measured using validated high-performance liquid chromatography for isoniazid and liquid chromatography–tandem mass spectrometry for rifampin.

The PK exposure-clinical outcome relationship will be evaluated based on the final aetiology of sepsis by comparing Cmax, Tmax, clearance (CL/F) and AUC to markers of early clinical recovery. Isoniazid and rifampin PK parameters will serve as exposure variables. Early assessments of clinical improvement are the outcome measures as continuous-valued variables, including time to durable normalisation of temperature,²⁰ time to ambulation,²¹ Karnofsky score,¹¹ length of hospitalisation, and time to death, stratified by final aetiology of sepsis categorization. These endpoints will be compared with general linear models or Wilcoxon rank-sum tests, as appropriate. Death will be considered a competing risk.

Overall trial safety and planned interim analyses

The number and type of adverse events will be tabulated by treatment group and site. χ² tests will be used to compare the groups on the proportion of patients in each group experiencing severe adverse events. Analyses are planned for after 25%, 50%, 75% and 100% of participants have reached the primary endpoint determination. The interim analyses will be guided by Lan-Demets boundaries using the O’Brien Fleming spending function for efficacy and futility.²² The boundaries will be applied separately to the main effects of timing and dose. The study Data Safety Monitoring Board (DSMB) will have the responsibility for recommending changes to the study based on these interim analyses. These decisions could include terminating the study based on safety concerns, or terminating accrual to one or more of the anti-TB therapy groups. In the case that accrual to at least one group is terminated, the DSMB, with the assistance of the study statistician, will make a recommendation as to how remaining participants should be allocated.

Sample size calculation

Sample size calculations indicate that enrolling 109 participants per group (a total of 436 participants) yields sufficient power to meet the primary objectives of the trial, to examine the main effects of the timing of anti-TB therapy and the use of sepsis-specific dosing on 28-day mortality. To reach this goal, each of two regional sites in Moshi, Tanzania and Mbarara, Uganda will enrol 218 participants over a 3-year period, a requirement of 72–73 participants per country per year. This calculation allows for 20% of participants to be discharged (alive) prior to day 28. Kaplan-Meier curves will be used to estimate the survival distribution for each of the four groups, estimating and comparing 28-day mortality based on the complementary log-log transformation.²³

The sample size was calculated to give 80% power, with a two-sided significance level of 5%, for testing each of the main effects of timing and dose on 28-day mortality, assuming a 28-day mortality of 45% in the diagnosis-dependent timing/conventional dose group (upper left cell ‘a’ in figure 2), 32% in each of the diagnosis-dependent timing/sepsis-specific dosing and immediate timing/conventional dose groups (off-diagonal cells ‘b’ and ‘c’ in the figure 2), and 19% in the immediate timing, sepsis-specific dose group (lower right cell ‘d’ in the figure 2). The calculations allow for a 20% loss to follow-up. An interaction plot for these assumed proportions is shown in figure 4.

Figure 4. Interaction plot of estimated effects of immediate and sepsis-specific dosing strategies in the ATLAS trial. ATLAS, A randomised clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa.

Data availability

This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, the ATLAS trial is registered at ClinicalTrials.gov; information and results from this trial will be submitted to ClinicalTrials.gov. In addition, we will publish results in peer-reviewed journals. Data from this study may be requested 5 years after the completion of the primary endpoint by contacting the principal investigators Moore and Heysell; however, a portion of data will be deposited in a publically accessible repository (eg, NIH TB Portals), as per NIH guidelines.

Patient and public involvement

As we prepared the trial protocol to submit for funding, we convened community advisory boards in both Tanzania and Uganda composed of lay stakeholders, religious leaders, and non-affiliated medical personnel to discuss the merits of the study to discuss the trial. The response from both Tanzanian and Ugandan community advisory boards was overwhelmingly supportive of the trial and for inclusion of the conventional dosing arm. The results of the study trial will be disseminated in the lay press, scientific conferences, and in peer-reviewed journals.

Discussion

Here, we present the ATLAS trial, a 2×2 factorial randomised clinical trial which aims to determine whether immediate and/or sepsis-specific dosing will improve 28-day mortality for study participants admitted to hospital with HIV and sepsis in Tanzania and Uganda. In doing so, we will determine the optimal content, timing, and dosing of antimicrobial therapy for sepsis in areas with a high HIV and TB prevalence in sub-Saharan Africa.

The WHO endorses a stepwise empirical initiation of anti-TB therapy among patients who are unable to be tested for TB by sputum smear and/or urine LAM, or have been tested but have negative results. Specifically, seriously ill hospitalised patients in HIV-endemic settings with a history of prolonged cough should receive anti-TB therapy only if they have not demonstrated clinical improvement while receiving routine parenteral antibiotics for 3–5 days. In a study of 467 patients from Tanzania, this stepwise treatment algorithm led to missed treatment in 48% of patients who ultimately had TB positive sputum cultures.²⁴ These data suggest that additional survival benefit could be accrued from early anti-TB therapy.

There are other published clinical trials of empirical anti-TB therapy in participants with HIV. The REMEMBER study was a clinical trial of empirical combination anti-TB therapy for active TB disease compared with isoniazid preventative therapy in outpatients with advanced HIV initiating antiretroviral therapy (ART) that took place at 18 sites in 10 countries.²⁵ Patients identified with active TB at screening were excluded. There was no difference in the primary outcome of death or unknown vital status 24 weeks after randomisation, which occurred in 5% of study participants. There was an increased rate of AIDS progression in the empirical anti-TB treatment group, mainly due to an increased incidence of TB. This finding was attributed to possibly increased discontinuation rates of ART and anti-TB therapy, diagnostic suspicion bias, and less likely unmasking TB-immune reconstitution inflammatory syndrome in the empirical anti-TB treatment group. Similarly, in the STATIS study conducted in six centres at two sites in Africa and two sites in Southeast Asia, there was no difference in death or invasive bacterial infection over 24 or 48 weeks among adults with advanced HIV who had not previously received ART who received systematic empirical anti-TB therapy when compared with those who received TB screening guided anti-TB therapy.²⁶ The overall mortality in this trial was 9%.

In these empirical anti-TB therapy trials in predominantly outpatients with HIV, the mortality was much lower than would be expected from a sepsis clinical trial where case fatality rates are expected to be 20%–50%. Furthermore, there is a higher likelihood of active disseminated TB in patients with HIV and sepsis compared with outpatients initiating ART. Therefore, the incremental benefit of empirical anti-TB therapy is likely to be higher in this ATLAS trial of anti-TB therapy for sepsis compared with prior studies of empirical anti-TB therapy in the outpatient setting. There are a myriad of non-TB infections that can lead to sepsis in this region including Enterobacteriaceae, non-Typhoid Salmonella, Staphylococcus aureus, and Streptococcus pneumoniae among others.^{5 27} It is also possible that there may be additional benefit of an anti-TB regimen that includes rifampin, in addition to the ceftriaxone that all study participants will receive, in the treatment of non-TB infections. We are further optimistic that our inclusion of a sepsis-specific dosing arm will provide additional discrimination of benefit among a patient population with a high likelihood of suboptimal exposure of anti-TB drugs when otherwise given at conventional doses.⁹

The ATLAS trial is anchored on early TB intervention and optimisation of the key anti-TB drugs, rifampin and isoniazid. The major potential limitation of the trial design is the lack of blinding, which could introduce bias based on known treatment allocation and potentially alter participant outcomes. However, it would be logistically challenging to mask immediate vs diagnosis-dependent anti-TB therapy, which could lead to allocation errors. Furthermore, given the high severity of illness of study participants, we expected a high case fatality rate which would require knowledge of the randomisation assignment and whether or not participants were receiving anti-TB therapy and at what dose. Another limitation of the trial is the potential for differences in clinical management of study participants at the two trial sites. To counter this limitation, the study teams, along with local clinicians, will oversee the management of the study participants and will adhere to the WHO guideline recommendations for the treatment of patients with HIV and suspected TB.¹⁵ Nonetheless, at its conclusion, the results of the ATLAS trial will provide the optimal content, dosing and timing of antimicrobial therapy for sepsis in high HIV and TB prevalent settings, which will have significant implications for national and international sepsis treatment guidelines.

Ethics and dissemination

The study is funded by the National Institutes of Health in the US and will be performed according to the Declaration of Helsinki and Good Clinical Practice. The trial is registered at ClinicalTrials.gov (NCT04618198). Institutional review board approval was conferred by the University of Virginia (HSR200253), the Tanzania National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/3664), and the Uganda National Council for Science and Technology (HS1272ES). Written informed consent will be obtained from each study participant (online supplemental file 1). Study results will be published in peer-reviewed journals and presented at international scientific conferences. We will also present our findings to our community advisory boards and aim to publish our findings in the lay press of Tanzania and Uganda.

Ethics statements

Patient consent for publication

Not applicable.

Footnote

Twitter @junjusamuel, @UVA_ID

BS and EN contributed equally.

CM and SGM contributed equally.

Contributors CCM, SKH, SGM, MC and CM conceptualised and designed the clinical trial with significant contributions from BS, EN, AL, DRB, MC and TT. MC led the statistical analysis plan. PB led the pharmacy plan. CCM and SKH secured funding for the clinical trial. RA created the REDCap database and randomisation procedures with MC. SM, AL, BS and MN led the implementation of the protocol in Tanzania with significant contributions from AC and CG. CM, EN, RM, and MN led the implementation of the protocol in Uganda with significant contributions from SJ and PT. All authors provided technical inputs in the proposal. SB, EN, CCM and SKH led the writing of the manuscript with contributions from all authors. All authors have approved the final version and agreed to be accountable for all aspects of the work related to accuracy and integrity. BS, EN, CCM, SKH, CM and SM are responsible for the overall content as guarantors.

Funding The principal sponsor of this study is National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology, and Infectious Diseases (NIH NIAID DMID), grant U01 AI150508. The funders had no role in the trial study design; collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

References

¹ Singer M, Deutschman CS, Seymour CW, et al. The third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–10. doi:10.1001/jama.2016.0287 http://www.ncbi.nlm.nih.gov/pubmed/26903338

² WHO. Sepsis. Available: http://www.who.int/sepsis/en/ [Accessed 27 Apr 2020 ].

³ Adhikari NKJ, Fowler RA, Bhagwanjee S, et al. Critical care and the global burden of critical illness in adults. Lancet 2010; 376: 1339–46. doi:10.1016/S0140-6736(10)60446-1 http://www.ncbi.nlm.nih.gov/pubmed/20934212

⁴ Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. Lancet 2020; 395: 200–11. doi:10.1016/S0140-6736(19)32989-7

⁵ Moore CC, Jacob ST, Banura P. Etiology of sepsis in Uganda using a quantitative PCR-based TaqMan array card. Clin Infect Dis.

⁶ Barr DA, Lewis JM, Feasey N, et al. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infect Dis 2020; 20: 742–52. doi:10.1016/S1473-3099(19)30695-4 http://www.ncbi.nlm.nih.gov/pubmed/32178764

⁷ Hazard RH, Kagina P, Kitayimbwa R, et al. Effect of empiric anti-Mycobacterium tuberculosis therapy on survival among human immunodeficiency virus-infected adults admitted with sepsis to a regional referral hospital in Uganda. Open Forum Infect Dis 2019; 6: ofz140. doi:10.1093/ofid/ofz140 http://www.ncbi.nlm.nih.gov/pubmed/31024977

⁸ Schutz C, Chirehwa M, Barr D, et al. Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. Br J Clin Pharmacol 2020; 86: 966–78. doi:10.1111/bcp.14207 http://www.ncbi.nlm.nih.gov/pubmed/31912537

⁹ Rao PS, Moore CC, Mbonde AA, et al. Population pharmacokinetics and significant under-dosing of anti-tuberculosis medications in people with HIV and critical illness. Antibiotics 2021; 10: 739. doi:10.3390/antibiotics10060739 http://www.ncbi.nlm.nih.gov/pubmed/34207312

¹⁰ Rudd KE, Seymour CW, Aluisio AR, et al. Association of the quick sequential (sepsis-related) organ failure assessment (qSOFA) score with excess hospital mortality in adults with suspected infection in low- and middle-income countries. JAMA 2018; 319: 2202–11. doi:10.1001/jama.2018.6229 http://www.ncbi.nlm.nih.gov/pubmed/29800114

¹¹ Jacob ST, Banura P, Baeten JM, et al. The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med 2012; 40: 2050–8. doi:10.1097/CCM.0b013e31824e65d7 http://www.ncbi.nlm.nih.gov/pubmed/22564958

¹² Katagira W, Walter ND, Den Boon S, et al. Empiric TB treatment of severely ill patients with HIV and presumed pulmonary TB improves survival. J Acquir Immune Defic Syndr 2016; 72: 297–303. doi:10.1097/QAI.0000000000000970 http://www.ncbi.nlm.nih.gov/pubmed/26918546

¹³ Andrews B, Muchemwa L, Kelly P, et al. Simplified severe sepsis protocol: a randomized controlled trial of modified early goal-directed therapy in Zambia. Crit Care Med 2014; 42: 2315–24. doi:10.1097/CCM.0000000000000541 http://www.ncbi.nlm.nih.gov/pubmed/25072757

¹⁴ Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017; 17: 873–81. doi:10.1016/S1473-3099(17)30243-8 http://www.ncbi.nlm.nih.gov/pubmed/28483415

¹⁵ WHO. Improving the diagnosis and treatment of smear-negative pulmonary and extra-pulmonary tuberculosis among adults and adolescents. Available: https://www.who.int/hiv/pub/tb/pulmonary/en/ [Accessed 7 Feb 2020 ].

¹⁶ Rubach MP, Maro VP, Bartlett JA, et al. Etiologies of illness among patients meeting integrated management of adolescent and adult illness district clinician manual criteria for severe infections in northern Tanzania: implications for empiric antimicrobial therapy. Am J Trop Med Hyg 2015; 92: 454–62. doi:10.4269/ajtmh.14-0496 http://www.ncbi.nlm.nih.gov/pubmed/25385866

¹⁷ Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA 2019; 321: 654–64. doi:10.1001/jama.2019.0071 http://www.ncbi.nlm.nih.gov/pubmed/30772908

¹⁸ Auma MA, Siedner MJ, Nyehangane D, et al. Malaria is an uncommon cause of adult sepsis in south-western Uganda. Malar J 2013; 12: 146. doi:10.1186/1475-2875-12-146 http://www.ncbi.nlm.nih.gov/pubmed/23634654

¹⁹ Brock GN, Barnes C, Ramirez JA, et al. How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Med Res Methodol 2011; 11: 144. doi:10.1186/1471-2288-11-144 http://www.ncbi.nlm.nih.gov/pubmed/22029846

²⁰ Bhavani SV, Carey KA, Gilbert ER, et al. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med 2019; 200: 327–35. doi:10.1164/rccm.201806-1197OC http://www.ncbi.nlm.nih.gov/pubmed/30789749

²¹ Nabayigga B, Kellett J, Opio MO. The alertness, gait and mortality of severely ill patients at two months after admission to a resource poor sub-Saharan hospital—Why is post-discharge surveillance not routine everywhere? Eur J Intern Med 2016; 28: 25–31. doi:10.1016/j.ejim.2015.12.011

²² O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–56. doi:10.2307/2530245 http://www.ncbi.nlm.nih.gov/pubmed/497341

²³ Klein JP, Logan B, Harhoff M, et al. Analyzing survival curves at a fixed point in time. Stat Med 2007; 26: 4505–19. doi:10.1002/sim.2864 http://www.ncbi.nlm.nih.gov/pubmed/17348080

²⁴ Swai HF, Mugusi FM, Mbwambo JK. Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 2011; 4: 475. doi:10.1186/1756-0500-4-475 http://www.ncbi.nlm.nih.gov/pubmed/22044882

²⁵ Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016; 387: 1198–209. doi:10.1016/S0140-6736(16)00546-8 http://www.ncbi.nlm.nih.gov/pubmed/27025337

²⁶ Blanc F-X, Badje AD, Bonnet M, et al. Systematic or test-guided treatment for tuberculosis in HIV-infected adults. N Engl J Med 2020; 382: 2397–410. doi:10.1056/NEJMoa1910708 http://www.ncbi.nlm.nih.gov/pubmed/32558469

²⁷ Crump JA, Ramadhani HO, Morrissey AB, et al. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis 2011; 52: 341–8. doi:10.1093/cid/ciq103 http://www.ncbi.nlm.nih.gov/pubmed/21217181